nodes	percent_of_prediction	percent_of_DWPC	metapath
Thalidomide—TNF—chronic obstructive pulmonary disease	0.193	0.401	CbGaD
Thalidomide—CYP1A1—chronic obstructive pulmonary disease	0.147	0.305	CbGaD
Thalidomide—CYP1A2—chronic obstructive pulmonary disease	0.142	0.294	CbGaD
Thalidomide—PTGS1—Montelukast—chronic obstructive pulmonary disease	0.0476	0.186	CbGbCtD
Thalidomide—CYP2E1—Aminophylline—chronic obstructive pulmonary disease	0.0413	0.161	CbGbCtD
Thalidomide—CYP2C19—Formoterol—chronic obstructive pulmonary disease	0.0304	0.119	CbGbCtD
Thalidomide—CYP2C19—Arformoterol—chronic obstructive pulmonary disease	0.0304	0.119	CbGbCtD
Thalidomide—CYP2C9—Formoterol—chronic obstructive pulmonary disease	0.0253	0.0987	CbGbCtD
Thalidomide—CYP2C9—Arformoterol—chronic obstructive pulmonary disease	0.0253	0.0987	CbGbCtD
Thalidomide—CYP1A2—Aminophylline—chronic obstructive pulmonary disease	0.0239	0.0932	CbGbCtD
Thalidomide—CYP2C9—Montelukast—chronic obstructive pulmonary disease	0.0192	0.0748	CbGbCtD
Thalidomide—CYP2C19—Prednisone—chronic obstructive pulmonary disease	0.0128	0.0499	CbGbCtD
Thalidomide—NFKB1—respiratory system—chronic obstructive pulmonary disease	0.00207	0.0715	CbGeAlD
Thalidomide—PTGS2—leg—chronic obstructive pulmonary disease	0.0019	0.0657	CbGeAlD
Thalidomide—NFKB1—connective tissue—chronic obstructive pulmonary disease	0.00182	0.063	CbGeAlD
Thalidomide—CRBN—respiratory system—chronic obstructive pulmonary disease	0.00173	0.0599	CbGeAlD
Thalidomide—NFKB1—bronchus—chronic obstructive pulmonary disease	0.0017	0.0589	CbGeAlD
Thalidomide—FGFR2—respiratory system—chronic obstructive pulmonary disease	0.00155	0.0537	CbGeAlD
Thalidomide—NFKB1—trachea—chronic obstructive pulmonary disease	0.00153	0.0528	CbGeAlD
Thalidomide—Pomalidomide—TNF—chronic obstructive pulmonary disease	0.00146	0.413	CrCbGaD
Thalidomide—CRBN—bronchus—chronic obstructive pulmonary disease	0.00143	0.0493	CbGeAlD
Thalidomide—FGFR2—connective tissue—chronic obstructive pulmonary disease	0.00137	0.0473	CbGeAlD
Thalidomide—CRBN—trachea—chronic obstructive pulmonary disease	0.00128	0.0443	CbGeAlD
Thalidomide—FGFR2—smooth muscle tissue—chronic obstructive pulmonary disease	0.00125	0.0433	CbGeAlD
Thalidomide—NFKB1—lung—chronic obstructive pulmonary disease	0.0011	0.038	CbGeAlD
Thalidomide—Pomalidomide—CYP1A2—chronic obstructive pulmonary disease	0.00107	0.303	CrCbGaD
Thalidomide—CRBN—lung—chronic obstructive pulmonary disease	0.00092	0.0318	CbGeAlD
Thalidomide—FGFR2—lung—chronic obstructive pulmonary disease	0.000824	0.0285	CbGeAlD
Thalidomide—CYP1A2—respiratory system—chronic obstructive pulmonary disease	0.000569	0.0197	CbGeAlD
Thalidomide—CYP1A1—respiratory system—chronic obstructive pulmonary disease	0.000562	0.0194	CbGeAlD
Thalidomide—CYP3A5—respiratory system—chronic obstructive pulmonary disease	0.000549	0.019	CbGeAlD
Thalidomide—CYP2E1—respiratory system—chronic obstructive pulmonary disease	0.000512	0.0177	CbGeAlD
Thalidomide—Menadione—CYP1A1—chronic obstructive pulmonary disease	0.000509	0.144	CrCbGaD
Thalidomide—PTGS1—respiratory system—chronic obstructive pulmonary disease	0.000493	0.0171	CbGeAlD
Thalidomide—Menadione—CYP1A2—chronic obstructive pulmonary disease	0.00049	0.139	CrCbGaD
Thalidomide—PTGS2—respiratory system—chronic obstructive pulmonary disease	0.000472	0.0163	CbGeAlD
Thalidomide—CYP1A1—bronchus—chronic obstructive pulmonary disease	0.000462	0.016	CbGeAlD
Thalidomide—PTGS1—connective tissue—chronic obstructive pulmonary disease	0.000434	0.015	CbGeAlD
Thalidomide—PTGS2—connective tissue—chronic obstructive pulmonary disease	0.000415	0.0144	CbGeAlD
Thalidomide—CYP1A1—trachea—chronic obstructive pulmonary disease	0.000415	0.0144	CbGeAlD
Thalidomide—PTGS1—smooth muscle tissue—chronic obstructive pulmonary disease	0.000397	0.0138	CbGeAlD
Thalidomide—PTGS2—bronchus—chronic obstructive pulmonary disease	0.000388	0.0134	CbGeAlD
Thalidomide—PTGS2—smooth muscle tissue—chronic obstructive pulmonary disease	0.00038	0.0131	CbGeAlD
Thalidomide—PTGS1—trachea—chronic obstructive pulmonary disease	0.000365	0.0126	CbGeAlD
Thalidomide—PTGS2—trachea—chronic obstructive pulmonary disease	0.000348	0.0121	CbGeAlD
Thalidomide—CYP1A2—lung—chronic obstructive pulmonary disease	0.000302	0.0105	CbGeAlD
Thalidomide—CYP1A1—lung—chronic obstructive pulmonary disease	0.000298	0.0103	CbGeAlD
Thalidomide—CYP3A5—lung—chronic obstructive pulmonary disease	0.000292	0.0101	CbGeAlD
Thalidomide—CYP2E1—lung—chronic obstructive pulmonary disease	0.000272	0.00941	CbGeAlD
Thalidomide—PTGS1—lung—chronic obstructive pulmonary disease	0.000262	0.00907	CbGeAlD
Thalidomide—PTGS2—lung—chronic obstructive pulmonary disease	0.00025	0.00867	CbGeAlD
Thalidomide—Hyperkinesia—Prednisone—chronic obstructive pulmonary disease	0.000107	0.000817	CcSEcCtD
Thalidomide—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.000107	0.000816	CcSEcCtD
Thalidomide—Thrombocytopenia—Montelukast—chronic obstructive pulmonary disease	0.000106	0.000814	CcSEcCtD
Thalidomide—Abdominal distension—Prednisolone—chronic obstructive pulmonary disease	0.000106	0.000814	CcSEcCtD
Thalidomide—Sepsis—Prednisone—chronic obstructive pulmonary disease	0.000106	0.000813	CcSEcCtD
Thalidomide—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.000106	0.000808	CcSEcCtD
Thalidomide—Euphoric mood—Prednisone—chronic obstructive pulmonary disease	0.000105	0.000805	CcSEcCtD
Thalidomide—Oedema—Salbutamol—chronic obstructive pulmonary disease	0.000105	0.000802	CcSEcCtD
Thalidomide—Infection—Salbutamol—chronic obstructive pulmonary disease	0.000104	0.000797	CcSEcCtD
Thalidomide—Hypotension—Formoterol—chronic obstructive pulmonary disease	0.000104	0.000794	CcSEcCtD
Thalidomide—Hypotension—Arformoterol—chronic obstructive pulmonary disease	0.000104	0.000794	CcSEcCtD
Thalidomide—Pancreatitis—Prednisolone—chronic obstructive pulmonary disease	0.000104	0.000793	CcSEcCtD
Thalidomide—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.000103	0.000789	CcSEcCtD
Thalidomide—Shock—Salbutamol—chronic obstructive pulmonary disease	0.000103	0.000789	CcSEcCtD
Thalidomide—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.000103	0.000786	CcSEcCtD
Thalidomide—Thrombophlebitis—Prednisone—chronic obstructive pulmonary disease	0.000103	0.000785	CcSEcCtD
Thalidomide—Tachycardia—Salbutamol—chronic obstructive pulmonary disease	0.000102	0.000783	CcSEcCtD
Thalidomide—Diabetes mellitus—Prednisone—chronic obstructive pulmonary disease	0.000102	0.000782	CcSEcCtD
Thalidomide—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.000102	0.000779	CcSEcCtD
Thalidomide—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.000101	0.000775	CcSEcCtD
Thalidomide—Hyperhidrosis—Salbutamol—chronic obstructive pulmonary disease	0.000101	0.000775	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	0.000101	0.000774	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000101	0.000774	CcSEcCtD
Thalidomide—Insomnia—Formoterol—chronic obstructive pulmonary disease	0.0001	0.000768	CcSEcCtD
Thalidomide—Insomnia—Arformoterol—chronic obstructive pulmonary disease	0.0001	0.000768	CcSEcCtD
Thalidomide—Anorexia—Salbutamol—chronic obstructive pulmonary disease	9.98e-05	0.000764	CcSEcCtD
Thalidomide—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	9.97e-05	0.000763	CcSEcCtD
Thalidomide—Vascular purpura—Prednisone—chronic obstructive pulmonary disease	9.93e-05	0.00076	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	9.9e-05	0.000758	CcSEcCtD
Thalidomide—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	9.89e-05	0.000757	CcSEcCtD
Thalidomide—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	9.89e-05	0.000757	CcSEcCtD
Thalidomide—Somnolence—Arformoterol—chronic obstructive pulmonary disease	9.86e-05	0.000755	CcSEcCtD
Thalidomide—Somnolence—Formoterol—chronic obstructive pulmonary disease	9.86e-05	0.000755	CcSEcCtD
Thalidomide—Insomnia—Montelukast—chronic obstructive pulmonary disease	9.82e-05	0.000752	CcSEcCtD
Thalidomide—Cardiac failure congestive—Prednisone—chronic obstructive pulmonary disease	9.79e-05	0.00075	CcSEcCtD
Thalidomide—Hypotension—Salbutamol—chronic obstructive pulmonary disease	9.78e-05	0.000749	CcSEcCtD
Thalidomide—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	9.76e-05	0.000748	CcSEcCtD
Thalidomide—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	9.76e-05	0.000748	CcSEcCtD
Thalidomide—Paraesthesia—Montelukast—chronic obstructive pulmonary disease	9.75e-05	0.000747	CcSEcCtD
Thalidomide—Pruritus—Tiotropium—chronic obstructive pulmonary disease	9.72e-05	0.000744	CcSEcCtD
Thalidomide—Injury—Prednisone—chronic obstructive pulmonary disease	9.66e-05	0.00074	CcSEcCtD
Thalidomide—Somnolence—Montelukast—chronic obstructive pulmonary disease	9.66e-05	0.000739	CcSEcCtD
Thalidomide—Dizziness—Aminophylline—chronic obstructive pulmonary disease	9.64e-05	0.000738	CcSEcCtD
Thalidomide—Weight increased—Prednisolone—chronic obstructive pulmonary disease	9.61e-05	0.000736	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	9.57e-05	0.000733	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	9.57e-05	0.000733	CcSEcCtD
Thalidomide—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	9.56e-05	0.000732	CcSEcCtD
Thalidomide—Fatigue—Formoterol—chronic obstructive pulmonary disease	9.56e-05	0.000732	CcSEcCtD
Thalidomide—Fatigue—Arformoterol—chronic obstructive pulmonary disease	9.56e-05	0.000732	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	9.54e-05	0.000731	CcSEcCtD
Thalidomide—Pain—Arformoterol—chronic obstructive pulmonary disease	9.48e-05	0.000726	CcSEcCtD
Thalidomide—Constipation—Formoterol—chronic obstructive pulmonary disease	9.48e-05	0.000726	CcSEcCtD
Thalidomide—Constipation—Arformoterol—chronic obstructive pulmonary disease	9.48e-05	0.000726	CcSEcCtD
Thalidomide—Pain—Formoterol—chronic obstructive pulmonary disease	9.48e-05	0.000726	CcSEcCtD
Thalidomide—Insomnia—Salbutamol—chronic obstructive pulmonary disease	9.47e-05	0.000725	CcSEcCtD
Thalidomide—Amnesia—Prednisone—chronic obstructive pulmonary disease	9.45e-05	0.000724	CcSEcCtD
Thalidomide—Increased appetite—Prednisone—chronic obstructive pulmonary disease	9.45e-05	0.000724	CcSEcCtD
Thalidomide—Paraesthesia—Salbutamol—chronic obstructive pulmonary disease	9.4e-05	0.00072	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	9.38e-05	0.000718	CcSEcCtD
Thalidomide—Fatigue—Montelukast—chronic obstructive pulmonary disease	9.36e-05	0.000717	CcSEcCtD
Thalidomide—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	9.34e-05	0.000715	CcSEcCtD
Thalidomide—Somnolence—Salbutamol—chronic obstructive pulmonary disease	9.31e-05	0.000713	CcSEcCtD
Thalidomide—Pain—Montelukast—chronic obstructive pulmonary disease	9.29e-05	0.000711	CcSEcCtD
Thalidomide—Acute coronary syndrome—Prednisolone—chronic obstructive pulmonary disease	9.28e-05	0.000711	CcSEcCtD
Thalidomide—Vomiting—Aminophylline—chronic obstructive pulmonary disease	9.26e-05	0.000709	CcSEcCtD
Thalidomide—Myocardial infarction—Prednisolone—chronic obstructive pulmonary disease	9.23e-05	0.000707	CcSEcCtD
Thalidomide—Neuropathy peripheral—Prednisolone—chronic obstructive pulmonary disease	9.23e-05	0.000707	CcSEcCtD
Thalidomide—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	9.22e-05	0.000706	CcSEcCtD
Thalidomide—Purpura—Prednisone—chronic obstructive pulmonary disease	9.21e-05	0.000705	CcSEcCtD
Thalidomide—Rash—Aminophylline—chronic obstructive pulmonary disease	9.19e-05	0.000704	CcSEcCtD
Thalidomide—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	9.18e-05	0.000703	CcSEcCtD
Thalidomide—Conjunctivitis—Prednisolone—chronic obstructive pulmonary disease	9.15e-05	0.000701	CcSEcCtD
Thalidomide—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	9.14e-05	0.0007	CcSEcCtD
Thalidomide—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	9.14e-05	0.0007	CcSEcCtD
Thalidomide—Headache—Aminophylline—chronic obstructive pulmonary disease	9.13e-05	0.000699	CcSEcCtD
Thalidomide—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	9.1e-05	0.000697	CcSEcCtD
Thalidomide—Cardiac failure—Prednisone—chronic obstructive pulmonary disease	9.1e-05	0.000697	CcSEcCtD
Thalidomide—Dizziness—Tiotropium—chronic obstructive pulmonary disease	9.09e-05	0.000696	CcSEcCtD
Thalidomide—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	9.07e-05	0.000694	CcSEcCtD
Thalidomide—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	9.07e-05	0.000694	CcSEcCtD
Thalidomide—Lethargy—Prednisone—chronic obstructive pulmonary disease	9.06e-05	0.000694	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	9.04e-05	0.000692	CcSEcCtD
Thalidomide—Fatigue—Salbutamol—chronic obstructive pulmonary disease	9.03e-05	0.000691	CcSEcCtD
Thalidomide—Constipation—Salbutamol—chronic obstructive pulmonary disease	8.95e-05	0.000686	CcSEcCtD
Thalidomide—Pain—Salbutamol—chronic obstructive pulmonary disease	8.95e-05	0.000686	CcSEcCtD
Thalidomide—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	8.88e-05	0.00068	CcSEcCtD
Thalidomide—Gastrointestinal haemorrhage—Prednisone—chronic obstructive pulmonary disease	8.88e-05	0.00068	CcSEcCtD
Thalidomide—Osteoarthritis—Prednisone—chronic obstructive pulmonary disease	8.88e-05	0.00068	CcSEcCtD
Thalidomide—Urticaria—Formoterol—chronic obstructive pulmonary disease	8.81e-05	0.000675	CcSEcCtD
Thalidomide—Urticaria—Arformoterol—chronic obstructive pulmonary disease	8.81e-05	0.000675	CcSEcCtD
Thalidomide—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	8.77e-05	0.000671	CcSEcCtD
Thalidomide—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	8.77e-05	0.000671	CcSEcCtD
Thalidomide—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	8.77e-05	0.000671	CcSEcCtD
Thalidomide—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	8.77e-05	0.000671	CcSEcCtD
Thalidomide—Affect lability—Prednisone—chronic obstructive pulmonary disease	8.74e-05	0.000669	CcSEcCtD
Thalidomide—Vomiting—Tiotropium—chronic obstructive pulmonary disease	8.74e-05	0.000669	CcSEcCtD
Thalidomide—Psychotic disorder—Prednisone—chronic obstructive pulmonary disease	8.67e-05	0.000664	CcSEcCtD
Thalidomide—Rash—Tiotropium—chronic obstructive pulmonary disease	8.66e-05	0.000663	CcSEcCtD
Thalidomide—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	8.66e-05	0.000663	CcSEcCtD
Thalidomide—Nausea—Aminophylline—chronic obstructive pulmonary disease	8.65e-05	0.000663	CcSEcCtD
Thalidomide—Urticaria—Montelukast—chronic obstructive pulmonary disease	8.63e-05	0.000661	CcSEcCtD
Thalidomide—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	8.63e-05	0.000661	CcSEcCtD
Thalidomide—Headache—Tiotropium—chronic obstructive pulmonary disease	8.61e-05	0.000659	CcSEcCtD
Thalidomide—Bradycardia—Prednisolone—chronic obstructive pulmonary disease	8.61e-05	0.000659	CcSEcCtD
Thalidomide—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	8.59e-05	0.000658	CcSEcCtD
Thalidomide—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	8.59e-05	0.000658	CcSEcCtD
Thalidomide—Face oedema—Prednisone—chronic obstructive pulmonary disease	8.57e-05	0.000656	CcSEcCtD
Thalidomide—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	8.56e-05	0.000656	CcSEcCtD
Thalidomide—Cardiac arrest—Prednisone—chronic obstructive pulmonary disease	8.44e-05	0.000647	CcSEcCtD
Thalidomide—Mood swings—Prednisone—chronic obstructive pulmonary disease	8.41e-05	0.000644	CcSEcCtD
Thalidomide—Urticaria—Salbutamol—chronic obstructive pulmonary disease	8.32e-05	0.000637	CcSEcCtD
Thalidomide—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	8.28e-05	0.000634	CcSEcCtD
Thalidomide—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	8.28e-05	0.000634	CcSEcCtD
Thalidomide—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	8.17e-05	0.000626	CcSEcCtD
Thalidomide—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	8.17e-05	0.000626	CcSEcCtD
Thalidomide—Nausea—Tiotropium—chronic obstructive pulmonary disease	8.16e-05	0.000625	CcSEcCtD
Thalidomide—Visual impairment—Prednisolone—chronic obstructive pulmonary disease	8.15e-05	0.000624	CcSEcCtD
Thalidomide—Dry skin—Prednisone—chronic obstructive pulmonary disease	8.14e-05	0.000623	CcSEcCtD
Thalidomide—Hypokalaemia—Prednisone—chronic obstructive pulmonary disease	8.08e-05	0.000619	CcSEcCtD
Thalidomide—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	8e-05	0.000613	CcSEcCtD
Thalidomide—Asthenia—Formoterol—chronic obstructive pulmonary disease	7.96e-05	0.000609	CcSEcCtD
Thalidomide—Asthenia—Arformoterol—chronic obstructive pulmonary disease	7.96e-05	0.000609	CcSEcCtD
Thalidomide—Pruritus—Arformoterol—chronic obstructive pulmonary disease	7.85e-05	0.000601	CcSEcCtD
Thalidomide—Pruritus—Formoterol—chronic obstructive pulmonary disease	7.85e-05	0.000601	CcSEcCtD
Thalidomide—Alanine aminotransferase increased—Prednisone—chronic obstructive pulmonary disease	7.83e-05	0.0006	CcSEcCtD
Thalidomide—Muscular weakness—Prednisone—chronic obstructive pulmonary disease	7.83e-05	0.0006	CcSEcCtD
Thalidomide—Asthenia—Montelukast—chronic obstructive pulmonary disease	7.79e-05	0.000597	CcSEcCtD
Thalidomide—Abdominal distension—Prednisone—chronic obstructive pulmonary disease	7.73e-05	0.000592	CcSEcCtD
Thalidomide—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	7.71e-05	0.000591	CcSEcCtD
Thalidomide—Pruritus—Montelukast—chronic obstructive pulmonary disease	7.68e-05	0.000588	CcSEcCtD
Thalidomide—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	7.59e-05	0.000581	CcSEcCtD
Thalidomide—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	7.59e-05	0.000581	CcSEcCtD
Thalidomide—Arrhythmia—Prednisolone—chronic obstructive pulmonary disease	7.55e-05	0.000578	CcSEcCtD
Thalidomide—Pancreatitis—Prednisone—chronic obstructive pulmonary disease	7.52e-05	0.000576	CcSEcCtD
Thalidomide—Asthenia—Salbutamol—chronic obstructive pulmonary disease	7.51e-05	0.000575	CcSEcCtD
Thalidomide—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	7.43e-05	0.000569	CcSEcCtD
Thalidomide—Pruritus—Salbutamol—chronic obstructive pulmonary disease	7.41e-05	0.000567	CcSEcCtD
Thalidomide—Dizziness—Formoterol—chronic obstructive pulmonary disease	7.33e-05	0.000562	CcSEcCtD
Thalidomide—Dizziness—Arformoterol—chronic obstructive pulmonary disease	7.33e-05	0.000562	CcSEcCtD
Thalidomide—Dizziness—Montelukast—chronic obstructive pulmonary disease	7.18e-05	0.00055	CcSEcCtD
Thalidomide—Neutropenia—Prednisone—chronic obstructive pulmonary disease	7.18e-05	0.00055	CcSEcCtD
Thalidomide—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	7.16e-05	0.000549	CcSEcCtD
Thalidomide—Erectile dysfunction—Prednisone—chronic obstructive pulmonary disease	7.07e-05	0.000541	CcSEcCtD
Thalidomide—Vomiting—Formoterol—chronic obstructive pulmonary disease	7.05e-05	0.00054	CcSEcCtD
Thalidomide—Vomiting—Arformoterol—chronic obstructive pulmonary disease	7.05e-05	0.00054	CcSEcCtD
Thalidomide—Rash—Arformoterol—chronic obstructive pulmonary disease	6.99e-05	0.000535	CcSEcCtD
Thalidomide—Rash—Formoterol—chronic obstructive pulmonary disease	6.99e-05	0.000535	CcSEcCtD
Thalidomide—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	6.99e-05	0.000535	CcSEcCtD
Thalidomide—Dermatitis—Formoterol—chronic obstructive pulmonary disease	6.99e-05	0.000535	CcSEcCtD
Thalidomide—Weight increased—Prednisone—chronic obstructive pulmonary disease	6.98e-05	0.000535	CcSEcCtD
Thalidomide—Headache—Arformoterol—chronic obstructive pulmonary disease	6.95e-05	0.000532	CcSEcCtD
Thalidomide—Headache—Formoterol—chronic obstructive pulmonary disease	6.95e-05	0.000532	CcSEcCtD
Thalidomide—Weight decreased—Prednisone—chronic obstructive pulmonary disease	6.94e-05	0.000532	CcSEcCtD
Thalidomide—Vision blurred—Prednisolone—chronic obstructive pulmonary disease	6.94e-05	0.000531	CcSEcCtD
Thalidomide—Dizziness—Salbutamol—chronic obstructive pulmonary disease	6.92e-05	0.00053	CcSEcCtD
Thalidomide—Hyperglycaemia—Prednisone—chronic obstructive pulmonary disease	6.92e-05	0.00053	CcSEcCtD
Thalidomide—Vomiting—Montelukast—chronic obstructive pulmonary disease	6.91e-05	0.000529	CcSEcCtD
Thalidomide—Rash—Montelukast—chronic obstructive pulmonary disease	6.85e-05	0.000524	CcSEcCtD
Thalidomide—Dermatitis—Montelukast—chronic obstructive pulmonary disease	6.84e-05	0.000524	CcSEcCtD
Thalidomide—Ill-defined disorder—Prednisolone—chronic obstructive pulmonary disease	6.83e-05	0.000523	CcSEcCtD
Thalidomide—Depression—Prednisone—chronic obstructive pulmonary disease	6.82e-05	0.000522	CcSEcCtD
Thalidomide—Headache—Montelukast—chronic obstructive pulmonary disease	6.8e-05	0.000521	CcSEcCtD
Thalidomide—Acute coronary syndrome—Prednisone—chronic obstructive pulmonary disease	6.75e-05	0.000517	CcSEcCtD
Thalidomide—Angioedema—Prednisolone—chronic obstructive pulmonary disease	6.72e-05	0.000515	CcSEcCtD
Thalidomide—Neuropathy peripheral—Prednisone—chronic obstructive pulmonary disease	6.71e-05	0.000514	CcSEcCtD
Thalidomide—Myocardial infarction—Prednisone—chronic obstructive pulmonary disease	6.71e-05	0.000514	CcSEcCtD
Thalidomide—Vomiting—Salbutamol—chronic obstructive pulmonary disease	6.66e-05	0.00051	CcSEcCtD
Thalidomide—Malaise—Prednisolone—chronic obstructive pulmonary disease	6.64e-05	0.000508	CcSEcCtD
Thalidomide—Vertigo—Prednisolone—chronic obstructive pulmonary disease	6.61e-05	0.000506	CcSEcCtD
Thalidomide—Rash—Salbutamol—chronic obstructive pulmonary disease	6.6e-05	0.000506	CcSEcCtD
Thalidomide—Syncope—Prednisolone—chronic obstructive pulmonary disease	6.6e-05	0.000505	CcSEcCtD
Thalidomide—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	6.6e-05	0.000505	CcSEcCtD
Thalidomide—Nausea—Arformoterol—chronic obstructive pulmonary disease	6.59e-05	0.000504	CcSEcCtD
Thalidomide—Nausea—Formoterol—chronic obstructive pulmonary disease	6.59e-05	0.000504	CcSEcCtD
Thalidomide—Headache—Salbutamol—chronic obstructive pulmonary disease	6.56e-05	0.000502	CcSEcCtD
Thalidomide—Loss of consciousness—Prednisolone—chronic obstructive pulmonary disease	6.47e-05	0.000495	CcSEcCtD
Thalidomide—Nausea—Montelukast—chronic obstructive pulmonary disease	6.45e-05	0.000494	CcSEcCtD
Thalidomide—Convulsion—Prednisolone—chronic obstructive pulmonary disease	6.38e-05	0.000488	CcSEcCtD
Thalidomide—Hypertension—Prednisolone—chronic obstructive pulmonary disease	6.35e-05	0.000487	CcSEcCtD
Thalidomide—Bradycardia—Prednisone—chronic obstructive pulmonary disease	6.25e-05	0.000479	CcSEcCtD
Thalidomide—Nausea—Salbutamol—chronic obstructive pulmonary disease	6.22e-05	0.000476	CcSEcCtD
Thalidomide—Discomfort—Prednisolone—chronic obstructive pulmonary disease	6.19e-05	0.000474	CcSEcCtD
Thalidomide—Oedema—Prednisolone—chronic obstructive pulmonary disease	6.01e-05	0.00046	CcSEcCtD
Thalidomide—Shock—Prednisolone—chronic obstructive pulmonary disease	5.91e-05	0.000452	CcSEcCtD
Thalidomide—Tachycardia—Prednisolone—chronic obstructive pulmonary disease	5.86e-05	0.000449	CcSEcCtD
Thalidomide—Hyperhidrosis—Prednisolone—chronic obstructive pulmonary disease	5.81e-05	0.000445	CcSEcCtD
Thalidomide—Eye disorder—Prednisone—chronic obstructive pulmonary disease	5.74e-05	0.00044	CcSEcCtD
Thalidomide—Angiopathy—Prednisone—chronic obstructive pulmonary disease	5.57e-05	0.000427	CcSEcCtD
Thalidomide—Immune system disorder—Prednisone—chronic obstructive pulmonary disease	5.55e-05	0.000425	CcSEcCtD
Thalidomide—Arrhythmia—Prednisone—chronic obstructive pulmonary disease	5.49e-05	0.00042	CcSEcCtD
Thalidomide—Insomnia—Prednisolone—chronic obstructive pulmonary disease	5.43e-05	0.000416	CcSEcCtD
Thalidomide—Alopecia—Prednisone—chronic obstructive pulmonary disease	5.43e-05	0.000416	CcSEcCtD
Thalidomide—Paraesthesia—Prednisolone—chronic obstructive pulmonary disease	5.39e-05	0.000413	CcSEcCtD
Thalidomide—Mental disorder—Prednisone—chronic obstructive pulmonary disease	5.38e-05	0.000412	CcSEcCtD
Thalidomide—Malnutrition—Prednisone—chronic obstructive pulmonary disease	5.35e-05	0.000409	CcSEcCtD
Thalidomide—Pain—Prednisolone—chronic obstructive pulmonary disease	5.14e-05	0.000393	CcSEcCtD
Thalidomide—Vision blurred—Prednisone—chronic obstructive pulmonary disease	5.04e-05	0.000386	CcSEcCtD
Thalidomide—Ill-defined disorder—Prednisone—chronic obstructive pulmonary disease	4.96e-05	0.00038	CcSEcCtD
Thalidomide—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	4.95e-05	0.000379	CcSEcCtD
Thalidomide—Anaemia—Prednisone—chronic obstructive pulmonary disease	4.94e-05	0.000378	CcSEcCtD
Thalidomide—Agitation—Prednisone—chronic obstructive pulmonary disease	4.91e-05	0.000376	CcSEcCtD
Thalidomide—Angioedema—Prednisone—chronic obstructive pulmonary disease	4.89e-05	0.000374	CcSEcCtD
Thalidomide—Malaise—Prednisone—chronic obstructive pulmonary disease	4.82e-05	0.000369	CcSEcCtD
Thalidomide—Vertigo—Prednisone—chronic obstructive pulmonary disease	4.8e-05	0.000368	CcSEcCtD
Thalidomide—Syncope—Prednisone—chronic obstructive pulmonary disease	4.8e-05	0.000367	CcSEcCtD
Thalidomide—Urticaria—Prednisolone—chronic obstructive pulmonary disease	4.77e-05	0.000365	CcSEcCtD
Thalidomide—Loss of consciousness—Prednisone—chronic obstructive pulmonary disease	4.7e-05	0.00036	CcSEcCtD
Thalidomide—Convulsion—Prednisone—chronic obstructive pulmonary disease	4.63e-05	0.000355	CcSEcCtD
Thalidomide—Hypertension—Prednisone—chronic obstructive pulmonary disease	4.62e-05	0.000354	CcSEcCtD
Thalidomide—Arthralgia—Prednisone—chronic obstructive pulmonary disease	4.55e-05	0.000349	CcSEcCtD
Thalidomide—Myalgia—Prednisone—chronic obstructive pulmonary disease	4.55e-05	0.000349	CcSEcCtD
Thalidomide—Anxiety—Prednisone—chronic obstructive pulmonary disease	4.54e-05	0.000347	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	4.52e-05	0.000346	CcSEcCtD
Thalidomide—Discomfort—Prednisone—chronic obstructive pulmonary disease	4.5e-05	0.000344	CcSEcCtD
Thalidomide—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	4.42e-05	0.000339	CcSEcCtD
Thalidomide—Oedema—Prednisone—chronic obstructive pulmonary disease	4.36e-05	0.000334	CcSEcCtD
Thalidomide—Infection—Prednisone—chronic obstructive pulmonary disease	4.34e-05	0.000332	CcSEcCtD
Thalidomide—Shock—Prednisone—chronic obstructive pulmonary disease	4.29e-05	0.000329	CcSEcCtD
Thalidomide—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	4.28e-05	0.000328	CcSEcCtD
Thalidomide—Tachycardia—Prednisone—chronic obstructive pulmonary disease	4.26e-05	0.000326	CcSEcCtD
Thalidomide—Skin disorder—Prednisone—chronic obstructive pulmonary disease	4.24e-05	0.000325	CcSEcCtD
Thalidomide—Hyperhidrosis—Prednisone—chronic obstructive pulmonary disease	4.22e-05	0.000323	CcSEcCtD
Thalidomide—Anorexia—Prednisone—chronic obstructive pulmonary disease	4.16e-05	0.000319	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	3.98e-05	0.000304	CcSEcCtD
Thalidomide—Dizziness—Prednisolone—chronic obstructive pulmonary disease	3.97e-05	0.000304	CcSEcCtD
Thalidomide—Insomnia—Prednisone—chronic obstructive pulmonary disease	3.95e-05	0.000302	CcSEcCtD
Thalidomide—Paraesthesia—Prednisone—chronic obstructive pulmonary disease	3.92e-05	0.0003	CcSEcCtD
Thalidomide—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	3.84e-05	0.000294	CcSEcCtD
Thalidomide—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	3.79e-05	0.000291	CcSEcCtD
Thalidomide—Rash—Prednisolone—chronic obstructive pulmonary disease	3.79e-05	0.00029	CcSEcCtD
Thalidomide—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	3.78e-05	0.00029	CcSEcCtD
Thalidomide—Fatigue—Prednisone—chronic obstructive pulmonary disease	3.76e-05	0.000288	CcSEcCtD
Thalidomide—Headache—Prednisolone—chronic obstructive pulmonary disease	3.76e-05	0.000288	CcSEcCtD
Thalidomide—Constipation—Prednisone—chronic obstructive pulmonary disease	3.73e-05	0.000286	CcSEcCtD
Thalidomide—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	3.6e-05	0.000275	CcSEcCtD
Thalidomide—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	3.57e-05	0.000273	CcSEcCtD
Thalidomide—Nausea—Prednisolone—chronic obstructive pulmonary disease	3.57e-05	0.000273	CcSEcCtD
Thalidomide—Urticaria—Prednisone—chronic obstructive pulmonary disease	3.47e-05	0.000265	CcSEcCtD
Thalidomide—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	3.45e-05	0.000264	CcSEcCtD
Thalidomide—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	3.45e-05	0.000264	CcSEcCtD
Thalidomide—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	3.22e-05	0.000246	CcSEcCtD
Thalidomide—Asthenia—Prednisone—chronic obstructive pulmonary disease	3.13e-05	0.00024	CcSEcCtD
Thalidomide—Pruritus—Prednisone—chronic obstructive pulmonary disease	3.09e-05	0.000236	CcSEcCtD
Thalidomide—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	2.99e-05	0.000229	CcSEcCtD
Thalidomide—Dizziness—Prednisone—chronic obstructive pulmonary disease	2.89e-05	0.000221	CcSEcCtD
Thalidomide—Vomiting—Prednisone—chronic obstructive pulmonary disease	2.77e-05	0.000212	CcSEcCtD
Thalidomide—Rash—Prednisone—chronic obstructive pulmonary disease	2.75e-05	0.000211	CcSEcCtD
Thalidomide—Dermatitis—Prednisone—chronic obstructive pulmonary disease	2.75e-05	0.000211	CcSEcCtD
Thalidomide—Headache—Prednisone—chronic obstructive pulmonary disease	2.73e-05	0.000209	CcSEcCtD
Thalidomide—Nausea—Prednisone—chronic obstructive pulmonary disease	2.59e-05	0.000199	CcSEcCtD
Thalidomide—CYP1A2—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	2.32e-05	0.000235	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—TLR2—chronic obstructive pulmonary disease	2.31e-05	0.000234	CbGpPWpGaD
Thalidomide—NFKB1—Cellular Senescence—IL6—chronic obstructive pulmonary disease	2.31e-05	0.000234	CbGpPWpGaD
Thalidomide—CYP1A2—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	2.29e-05	0.000232	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—TGFB1—chronic obstructive pulmonary disease	2.29e-05	0.000231	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 interactions—IL6—chronic obstructive pulmonary disease	2.28e-05	0.000231	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by FGFR in disease—IL6—chronic obstructive pulmonary disease	2.28e-05	0.000231	CbGpPWpGaD
Thalidomide—FGFR2—Fc epsilon receptor (FCERI) signaling—IL6—chronic obstructive pulmonary disease	2.28e-05	0.000231	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by EGFR—IL6—chronic obstructive pulmonary disease	2.26e-05	0.000229	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—EGFR—chronic obstructive pulmonary disease	2.24e-05	0.000227	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by EGFR in Cancer—IL6—chronic obstructive pulmonary disease	2.24e-05	0.000227	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by PDGF—IL6—chronic obstructive pulmonary disease	2.23e-05	0.000226	CbGpPWpGaD
Thalidomide—TNF—Apoptosis—TP53—chronic obstructive pulmonary disease	2.23e-05	0.000225	CbGpPWpGaD
Thalidomide—TNF—Regulation of toll-like receptor signaling pathway—IL6—chronic obstructive pulmonary disease	2.22e-05	0.000225	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—TLR2—chronic obstructive pulmonary disease	2.19e-05	0.000222	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—KL—chronic obstructive pulmonary disease	2.17e-05	0.00022	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	2.17e-05	0.00022	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—LEP—chronic obstructive pulmonary disease	2.16e-05	0.000218	CbGpPWpGaD
Thalidomide—CYP1A2—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	2.14e-05	0.000216	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—EGFR—chronic obstructive pulmonary disease	2.13e-05	0.000216	CbGpPWpGaD
Thalidomide—CYP1A2—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	2.11e-05	0.000213	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—APIP—chronic obstructive pulmonary disease	2.09e-05	0.000212	CbGpPWpGaD
Thalidomide—TNF—MAPK Signaling Pathway—TP53—chronic obstructive pulmonary disease	2.09e-05	0.000211	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—TGFB1—chronic obstructive pulmonary disease	2.08e-05	0.00021	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	2.07e-05	0.000209	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—KL—chronic obstructive pulmonary disease	2.06e-05	0.000209	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	2.05e-05	0.000208	CbGpPWpGaD
Thalidomide—FGFR2—Disease—HDAC2—chronic obstructive pulmonary disease	2.05e-05	0.000207	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—EGFR—chronic obstructive pulmonary disease	2.04e-05	0.000206	CbGpPWpGaD
Thalidomide—TNF—SIDS Susceptibility Pathways—IL6—chronic obstructive pulmonary disease	2.03e-05	0.000205	CbGpPWpGaD
Thalidomide—CYP1A2—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	2.03e-05	0.000205	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—EGFR—chronic obstructive pulmonary disease	2.02e-05	0.000205	CbGpPWpGaD
Thalidomide—FGFR2—NGF signalling via TRKA from the plasma membrane—IL6—chronic obstructive pulmonary disease	2.02e-05	0.000204	CbGpPWpGaD
Thalidomide—CYP1A2—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	2e-05	0.000202	CbGpPWpGaD
Thalidomide—PTGS2—Selenium Micronutrient Network—IL6—chronic obstructive pulmonary disease	1.98e-05	0.0002	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	1.96e-05	0.000198	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—TNF—chronic obstructive pulmonary disease	1.94e-05	0.000196	CbGpPWpGaD
Thalidomide—NFKB1—Cellular responses to stress—TP53—chronic obstructive pulmonary disease	1.91e-05	0.000193	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.91e-05	0.000193	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—APIP—chronic obstructive pulmonary disease	1.91e-05	0.000193	CbGpPWpGaD
Thalidomide—FGFR2—Disease—KL—chronic obstructive pulmonary disease	1.9e-05	0.000193	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	1.89e-05	0.000191	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—TP53—chronic obstructive pulmonary disease	1.88e-05	0.000191	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—GC—chronic obstructive pulmonary disease	1.86e-05	0.000188	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	1.82e-05	0.000184	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.8e-05	0.000182	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.79e-05	0.000181	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CD8A—chronic obstructive pulmonary disease	1.75e-05	0.000177	CbGpPWpGaD
Thalidomide—NFKB1—Cellular responses to stress—IL6—chronic obstructive pulmonary disease	1.75e-05	0.000177	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—GC—chronic obstructive pulmonary disease	1.75e-05	0.000177	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—GC—chronic obstructive pulmonary disease	1.74e-05	0.000176	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	1.73e-05	0.000175	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.72e-05	0.000174	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—TP53—chronic obstructive pulmonary disease	1.71e-05	0.000173	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—MMP9—chronic obstructive pulmonary disease	1.7e-05	0.000172	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.69e-05	0.000171	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	1.68e-05	0.00017	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—IL6—chronic obstructive pulmonary disease	1.67e-05	0.000169	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CD8A—chronic obstructive pulmonary disease	1.66e-05	0.000168	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GC—chronic obstructive pulmonary disease	1.65e-05	0.000167	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—IL6—chronic obstructive pulmonary disease	1.64e-05	0.000166	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—ERBB3—chronic obstructive pulmonary disease	1.63e-05	0.000165	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—APIP—chronic obstructive pulmonary disease	1.63e-05	0.000165	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.62e-05	0.000164	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.62e-05	0.000164	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—IL6—chronic obstructive pulmonary disease	1.57e-05	0.000159	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—IL6—chronic obstructive pulmonary disease	1.55e-05	0.000157	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—ERBB3—chronic obstructive pulmonary disease	1.55e-05	0.000156	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—chronic obstructive pulmonary disease	1.54e-05	0.000156	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.53e-05	0.000155	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—VEGFA—chronic obstructive pulmonary disease	1.53e-05	0.000155	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	1.51e-05	0.000153	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	1.49e-05	0.000151	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CRP—chronic obstructive pulmonary disease	1.49e-05	0.000151	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	1.43e-05	0.000145	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—TLR4—chronic obstructive pulmonary disease	1.43e-05	0.000144	CbGpPWpGaD
Thalidomide—FGFR2—Disease—ERBB3—chronic obstructive pulmonary disease	1.43e-05	0.000144	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—chronic obstructive pulmonary disease	1.42e-05	0.000143	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CRP—chronic obstructive pulmonary disease	1.41e-05	0.000143	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—KL—chronic obstructive pulmonary disease	1.41e-05	0.000142	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—TGFB1—chronic obstructive pulmonary disease	1.4e-05	0.000142	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—chronic obstructive pulmonary disease	1.39e-05	0.00014	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.39e-05	0.00014	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—EGFR—chronic obstructive pulmonary disease	1.38e-05	0.000139	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	1.37e-05	0.000139	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	1.37e-05	0.000139	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	1.36e-05	0.000138	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—TLR4—chronic obstructive pulmonary disease	1.36e-05	0.000137	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GC—chronic obstructive pulmonary disease	1.35e-05	0.000136	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—KL—chronic obstructive pulmonary disease	1.33e-05	0.000135	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—chronic obstructive pulmonary disease	1.32e-05	0.000134	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—TNF—chronic obstructive pulmonary disease	1.31e-05	0.000133	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—MMP9—chronic obstructive pulmonary disease	1.3e-05	0.000131	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.3e-05	0.000131	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.28e-05	0.000129	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.26e-05	0.000128	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—GCLC—chronic obstructive pulmonary disease	1.26e-05	0.000128	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.25e-05	0.000127	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	1.25e-05	0.000127	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.23e-05	0.000124	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GC—chronic obstructive pulmonary disease	1.23e-05	0.000124	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—EGFR—chronic obstructive pulmonary disease	1.22e-05	0.000123	CbGpPWpGaD
Thalidomide—FGFR2—Disease—NOS2—chronic obstructive pulmonary disease	1.19e-05	0.00012	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	1.18e-05	0.000119	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—EGFR—chronic obstructive pulmonary disease	1.17e-05	0.000118	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—VEGFA—chronic obstructive pulmonary disease	1.17e-05	0.000118	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—chronic obstructive pulmonary disease	1.16e-05	0.000118	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	1.16e-05	0.000118	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.16e-05	0.000117	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—EGFR—chronic obstructive pulmonary disease	1.15e-05	0.000117	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—CTGF—chronic obstructive pulmonary disease	1.15e-05	0.000116	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.14e-05	0.000116	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—EGFR—chronic obstructive pulmonary disease	1.11e-05	0.000112	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.1e-05	0.000111	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.08e-05	0.000109	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—TGFB1—chronic obstructive pulmonary disease	1.07e-05	0.000108	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.06e-05	0.000107	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—IL6—chronic obstructive pulmonary disease	1.06e-05	0.000107	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.05e-05	0.000107	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GC—chronic obstructive pulmonary disease	1.05e-05	0.000106	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—EGFR—chronic obstructive pulmonary disease	1.05e-05	0.000106	CbGpPWpGaD
Thalidomide—PTGS2—Disease—HDAC2—chronic obstructive pulmonary disease	1.02e-05	0.000103	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.01e-05	0.000103	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.01e-05	0.000103	CbGpPWpGaD
Thalidomide—FGFR2—Disease—SERPINE1—chronic obstructive pulmonary disease	1e-05	0.000101	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—GCLC—chronic obstructive pulmonary disease	1e-05	0.000101	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1e-05	0.000101	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	9.98e-06	0.000101	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	9.76e-06	9.87e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	9.62e-06	9.73e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—NOS3—chronic obstructive pulmonary disease	9.57e-06	9.68e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—GSTT1—chronic obstructive pulmonary disease	9.54e-06	9.65e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—GSTT1—chronic obstructive pulmonary disease	9.52e-06	9.63e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—KL—chronic obstructive pulmonary disease	9.46e-06	9.57e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—GCLC—chronic obstructive pulmonary disease	9.43e-06	9.54e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—LEP—chronic obstructive pulmonary disease	9.43e-06	9.54e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—GCLC—chronic obstructive pulmonary disease	9.41e-06	9.52e-05	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—IL6—chronic obstructive pulmonary disease	9.34e-06	9.45e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	9.34e-06	9.45e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IL1B—chronic obstructive pulmonary disease	9.29e-06	9.4e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—CTGF—chronic obstructive pulmonary disease	9.14e-06	9.25e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	9.1e-06	9.21e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GSTT1—chronic obstructive pulmonary disease	9e-06	9.1e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—LEP—chronic obstructive pulmonary disease	8.94e-06	9.05e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GCLC—chronic obstructive pulmonary disease	8.89e-06	8.99e-05	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—IL6—chronic obstructive pulmonary disease	8.87e-06	8.97e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—GSTP1—chronic obstructive pulmonary disease	8.85e-06	8.95e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IL1B—chronic obstructive pulmonary disease	8.82e-06	8.92e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—HMOX1—chronic obstructive pulmonary disease	8.73e-06	8.83e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CTGF—chronic obstructive pulmonary disease	8.61e-06	8.71e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CTGF—chronic obstructive pulmonary disease	8.59e-06	8.69e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—CYP1A2—chronic obstructive pulmonary disease	8.42e-06	8.52e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	8.29e-06	8.39e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—GSTM1—chronic obstructive pulmonary disease	8.13e-06	8.23e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CTGF—chronic obstructive pulmonary disease	8.11e-06	8.21e-05	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—IL6—chronic obstructive pulmonary disease	8.06e-06	8.15e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	7.93e-06	8.02e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CYP1A2—chronic obstructive pulmonary disease	7.91e-06	8e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	7.78e-06	7.87e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—CYP1A1—chronic obstructive pulmonary disease	7.71e-06	7.8e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	7.48e-06	7.56e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	7.4e-06	7.48e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GSTT1—chronic obstructive pulmonary disease	7.36e-06	7.45e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GCLC—chronic obstructive pulmonary disease	7.28e-06	7.36e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—ERBB3—chronic obstructive pulmonary disease	7.09e-06	7.17e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—EGFR—chronic obstructive pulmonary disease	7.08e-06	7.16e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	7.06e-06	7.14e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—GSTP1—chronic obstructive pulmonary disease	7.03e-06	7.11e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	7.02e-06	7.1e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—HMOX1—chronic obstructive pulmonary disease	6.93e-06	7.01e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	6.78e-06	6.86e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—EGFR—chronic obstructive pulmonary disease	6.72e-06	6.8e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GSTT1—chronic obstructive pulmonary disease	6.71e-06	6.79e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	6.7e-06	6.78e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CTGF—chronic obstructive pulmonary disease	6.64e-06	6.72e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GCLC—chronic obstructive pulmonary disease	6.63e-06	6.71e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—GSTP1—chronic obstructive pulmonary disease	6.61e-06	6.69e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—GSTP1—chronic obstructive pulmonary disease	6.6e-06	6.68e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—HMOX1—chronic obstructive pulmonary disease	6.52e-06	6.6e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—HMOX1—chronic obstructive pulmonary disease	6.51e-06	6.58e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—GSTM1—chronic obstructive pulmonary disease	6.46e-06	6.53e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—TGFB1—chronic obstructive pulmonary disease	6.33e-06	6.4e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	6.26e-06	6.34e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GSTP1—chronic obstructive pulmonary disease	6.24e-06	6.31e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—EGFR—chronic obstructive pulmonary disease	6.2e-06	6.28e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	6.19e-06	6.26e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—HMOX1—chronic obstructive pulmonary disease	6.15e-06	6.22e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—CYP1A1—chronic obstructive pulmonary disease	6.12e-06	6.19e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CYP1A2—chronic obstructive pulmonary disease	6.12e-06	6.19e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—GSTM1—chronic obstructive pulmonary disease	6.08e-06	6.15e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—GSTM1—chronic obstructive pulmonary disease	6.07e-06	6.13e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CTGF—chronic obstructive pulmonary disease	6.05e-06	6.12e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	5.94e-06	6.01e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—NOS2—chronic obstructive pulmonary disease	5.91e-06	5.98e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CYP1A1—chronic obstructive pulmonary disease	5.76e-06	5.83e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CYP1A1—chronic obstructive pulmonary disease	5.75e-06	5.82e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GSTT1—chronic obstructive pulmonary disease	5.74e-06	5.8e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GSTM1—chronic obstructive pulmonary disease	5.73e-06	5.8e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GCLC—chronic obstructive pulmonary disease	5.67e-06	5.74e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	5.67e-06	5.73e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CYP1A2—chronic obstructive pulmonary disease	5.58e-06	5.64e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IL6—chronic obstructive pulmonary disease	5.44e-06	5.51e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	5.38e-06	5.44e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	5.29e-06	5.35e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—ALB—chronic obstructive pulmonary disease	5.24e-06	5.3e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CTGF—chronic obstructive pulmonary disease	5.17e-06	5.23e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IL6—chronic obstructive pulmonary disease	5.16e-06	5.22e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GSTP1—chronic obstructive pulmonary disease	5.1e-06	5.16e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	5.09e-06	5.15e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—HMOX1—chronic obstructive pulmonary disease	5.03e-06	5.09e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—NOS3—chronic obstructive pulmonary disease	5.01e-06	5.07e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—SERPINE1—chronic obstructive pulmonary disease	4.98e-06	5.03e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	4.83e-06	4.88e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—IL6—chronic obstructive pulmonary disease	4.77e-06	4.82e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—NOS3—chronic obstructive pulmonary disease	4.75e-06	4.81e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GSTM1—chronic obstructive pulmonary disease	4.69e-06	4.74e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	4.67e-06	4.72e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GSTP1—chronic obstructive pulmonary disease	4.65e-06	4.71e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—HMOX1—chronic obstructive pulmonary disease	4.59e-06	4.64e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	4.58e-06	4.63e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CYP1A1—chronic obstructive pulmonary disease	4.45e-06	4.5e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	4.43e-06	4.48e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	4.34e-06	4.39e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GSTM1—chronic obstructive pulmonary disease	4.28e-06	4.32e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—ALB—chronic obstructive pulmonary disease	4.16e-06	4.21e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CYP1A1—chronic obstructive pulmonary disease	4.05e-06	4.1e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—NOS3—chronic obstructive pulmonary disease	3.98e-06	4.03e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GSTP1—chronic obstructive pulmonary disease	3.98e-06	4.02e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—HMOX1—chronic obstructive pulmonary disease	3.92e-06	3.97e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—ALB—chronic obstructive pulmonary disease	3.92e-06	3.96e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—ALB—chronic obstructive pulmonary disease	3.91e-06	3.95e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	3.84e-06	3.89e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—NOS3—chronic obstructive pulmonary disease	3.75e-06	3.79e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—NOS3—chronic obstructive pulmonary disease	3.74e-06	3.78e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ALB—chronic obstructive pulmonary disease	3.69e-06	3.73e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GSTM1—chronic obstructive pulmonary disease	3.65e-06	3.7e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TP53—chronic obstructive pulmonary disease	3.65e-06	3.69e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—NOS3—chronic obstructive pulmonary disease	3.53e-06	3.57e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	3.52e-06	3.56e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CYP1A1—chronic obstructive pulmonary disease	3.46e-06	3.5e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IL6—chronic obstructive pulmonary disease	3.34e-06	3.38e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—TGFB1—chronic obstructive pulmonary disease	3.14e-06	3.18e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—EGFR—chronic obstructive pulmonary disease	3.08e-06	3.12e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ALB—chronic obstructive pulmonary disease	3.02e-06	3.06e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—NOS3—chronic obstructive pulmonary disease	2.89e-06	2.92e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ALB—chronic obstructive pulmonary disease	2.76e-06	2.79e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—NOS3—chronic obstructive pulmonary disease	2.64e-06	2.67e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—IL6—chronic obstructive pulmonary disease	2.37e-06	2.4e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ALB—chronic obstructive pulmonary disease	2.35e-06	2.38e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—NOS3—chronic obstructive pulmonary disease	2.25e-06	2.28e-05	CbGpPWpGaD
